Product Program year 2019 Source: CMS Open Payments

Aggrastat (tirofiban HCl)

Drug Acute cardiovascular care.

NDC 25208-002-02

Open in the dashboard

General payments

$8,321

16 payments

Research payments

$58,054

2 payments

Through program year 2019, $8,321 in general payments and $58,054 in research payments were reported against Aggrastat (tirofiban HCl) (Acute cardiovascular care.).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2019 General $8,321 16
2019 Research $58,054 2

Breakdown

Who paid General payments · program year 2019
  1. Medicure Pharma Inc. $8,321 16 payments
Top recipients General payments · program year 2019
  1. Sandeep Krishnan Interventional Cardiology · Ashland, KY $5,740 69% · 3 payments
  2. Jose Garcia Mateo Endocrinology, Diabetes & Metabolism · Ponce, PR $1,500 18% · 1 payment
  3. M Chadi Alraies Interventional Cardiology · Detroit, MI $500 6% · 1 payment
  4. Merrill Krolick Interventional Cardiology · Largo, FL $74 <1% · 1 payment
  5. Joseph Carragher Interventional Cardiology · South Pasadena, FL $74 <1% · 1 payment

The top 5 of 14 recipients; each share is of general payments naming this product in 2019.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2019
  1. Interventional Cardiology Internal Medicine $6,484 78% · 7 practitioners
  2. Endocrinology, Diabetes & Metabolism Internal Medicine $1,500 18% · 1 practitioner
  3. Cardiovascular Disease Internal Medicine $159 2% · 3 practitioners
  4. Clinical Cardiac Electrophysiology Internal Medicine $74 <1% · 1 practitioner
  5. Internal Medicine $52 <1% · 1 practitioner

The top 5 of 6 specialties; each share is of general payments naming this product to practitioners with a specialty in 2019. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2019
  1. Oklahoma $3,000 36% · 1 recipient
  2. Kentucky $2,740 33% · 1 recipient
  3. Puerto Rico $1,500 18% · 1 recipient
  4. Ohio $500 6% · 1 recipient
  5. Florida $444 5% · 6 recipients

The top 5 of 9 states; each share is of general payments naming this product in 2019 where a state was reported.

The top 25 states, free in the app

16 general · 2 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2019

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record